Immunoinformatics approach for designing poly-epitope based vaccines

سال انتشار: 1400
نوع سند: مقاله کنفرانسی
زبان: انگلیسی
مشاهده: 222

نسخه کامل این مقاله ارائه نشده است و در دسترس نمی باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

IBIS10_156

تاریخ نمایه سازی: 5 تیر 1401

چکیده مقاله:

The primary purpose within all the immunizations is the ability of the vaccine to induce arobust immune response in a faster mode than the pathogen itself. Designing the best vaccinein the fastest time is very important. Reverse vaccinology employs bioinformatics to findproteins and epitopes that indicate antigenicity. Some of the advantages of this approach arereduced cost and time of vaccine development and facilitating antigen identificationselection. This method does not require the cultivation of risky microorganisms, allowing tostudy non-cultivate microorganisms and screening of all microorganism proteins fromgenome sequences, making them biologically safe. Additionally, their selectivity allowsaccurate activation of immune responses.Methods: We will highlight the immune-informatics and computational approach techniqueknown as reverse vaccinology to predict the potential epitope for designing poly epitopevaccines, including the T cell and B cell epitopes. Each epitope's antigenicity, toxicity, andallergenicity are checked; then, the selected epitopes are joined together via different linkers.Various physical-chemical properties of the poly-epitopes vaccine, including molecularweight (MW), isoelectric point (IP), stability index, half-life in vitro and in vivo, aliphaticindex, and grand average of hydropathicity (GRAVY), are estimated in silico. The threedimensional structureof the mentioned vaccine will be subjected to molecular dockingstudies with MHC-I and MHC-II molecules.Results: In the final, we selected the non-toxic and non-allergic epitopes with a highantigenicity score. These epitopes are linked together and indicate suitable properties.Conclusion: The proposed vaccine needs to be validated clinically to ensure its safety andimmunogenic profile.

نویسندگان

Elham Ghafouri

Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Hossein Khanahmad

Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran